Global Nucala Market Analysis 2017-2026 with Sales by Country - ResearchAndMarkets.com

DUBLIN--()--The "Nucala" report has been added to ResearchAndMarkets.com's offering.

Nucala (mepolizumab; GlaxoSmithKline) is a humanized monoclonal immunoglobulin G1 antibody that binds to interleukin (IL)-5, which plays a significant role in the activation, proliferation, and differentiation of eosinophils.

The drug inhibits the binding of IL-5 to the receptors on the surface of eosinophils, thereby reducing blood, tissue, and sputum eosinophil levels.

Nucala gained US and EU approvals for use in asthma in November 2015 and December 2015, respectively. In Japan, the drug was approved in March 2016.

Key Topics Covered

  1. Drug Overview
  2. Product Profiles
  3. Nucala: Chronic obstructive pulmonary disease (COPD)
  4. Nucala: Asthma

List of Figures

Figure 1: The authors drug assessment summary of Nucala for COPD

Figure 2: The authors drug assessment summary of Nucala for COPD

Figure 3: Nucala for asthma - SWOT analysis

Figure 4: The authors drug assessment summary of Nucala in asthma

Figure 5: The authors drug assessment summary of Nucala in asthma

Figure 6: Nucala sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: Nucala drug profile

Table 2: Nucala Phase III data in COPD

Table 3: Nucala drug profile

Table 4: Nucala pivotal trial data in asthma

Table 5: Nucala late-phase trial data in asthma

Table 6: Nucala Phase III trials in asthma

Table 7: Nucala sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26

For more information about this report visit https://www.researchandmarkets.com/r/reghkg

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Asthma Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Asthma Drugs